Free Trial
NASDAQ:ANNX

Annexon Q1 2024 Earnings Report

Annexon logo
$2.19 -0.16 (-6.81%)
Closing price 04:00 PM Eastern
Extended Trading
$2.17 -0.02 (-0.73%)
As of 07:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annexon EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.32
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Annexon Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Annexon Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Monday, May 13, 2024
Conference Call Time
4:00PM ET

Annexon Earnings Headlines

Jefferies Keeps Their Buy Rating on Annexon Biosciences (ANNX)
He’s been waiting for this set-up his entire career…
Jeff Brown has made some remarkable calls—Bitcoin at $240, Nvidia at 66¢, Tesla at $20—and now he says an event bigger than all of them combined is set to hit within the next 90 days. He calls it Hyper Acceleration, and it’s only happened twice before in U.S. history—each time producing some of the largest fortunes ever seen. On Wednesday, August 20 at 8 p.m. ET, Jeff will reveal the full details and share the names of two stocks he believes could soar 1,000% or more—free to attendees.tc pixel
Annexon Biosciences (ANNX) Receives a Buy from Wells Fargo
See More Annexon Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Annexon? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Annexon and other key companies, straight to your email.

About Annexon

Annexon (NASDAQ:ANNX), a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

View Annexon Profile

More Earnings Resources from MarketBeat